Following large‐scale cancer sequence analysis, mutations in other HR‐related genes such as CDK12, ATM and PALB2 were commonly found in mCRPC [11, 48, 49], and these non‐BRCA DNA repair genes could be used as alternative biomarkers to predict the sensitivity of PARPi. This evidence concerns the gene PALB2 and cancer.